 |
|
Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy
Hyung Woo Kim, Ju Sang Kim
Tuberc Respir Dis. 2018;81(1):6-12. Published online 2017 Dec 15 DOI: https://doi.org/10.4046/trd.2017.0052
|
|
Citations to this article as recorded by
 Evaluating the significance of latent tuberculosis infection treatment in high‐incidence countries
Ankur Gupta, Garhima Arora, Nandadulal Bairagi, Samrat Chatterjee
Mathematical Methods in the Applied Sciences.2025; 48(3): 4035. CrossRef The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway
Anjali Negi, Rashmi Sharma
European Journal of Medicinal Chemistry.2024; 265: 116058. CrossRef A Mathematical Model for the Impact of 3HP and Social Programme Implementation on the Incidence and Mortality of Tuberculosis: Study in Brazil
Erick Manuel Delgado Moya, Jose Alejandro Ordoñez, Felipe Alves Rubio, Mauro Niskier Sanchez, Robson Bruniera de Oliveira, Rodrigo Volmir Anderle, Davide Rasella
Bulletin of Mathematical Biology.2024;[Epub] CrossRef Aqueous extract‐mediated green synthesis of CuO nanoparticles: Potential anti‐tuberculosis agents
Zohreh Zamanian, Elahe Tajbakhsh, Nazila Arbab Soleimani, AbdolMajid Ghasemian
Food Science & Nutrition.2024; 12(8): 5907. CrossRef One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial
Hung-Ling Huang, Meng-Rui Lee, Chih-Hsin Lee, Meng-Hsuan Cheng, Po-Liang Lu, Chau-Chyun Sheu, Jann-Yuan Wang, Inn-Wen Chong, Jinn-Moon Yang
Clinical Microbiology and Infection.2024; 30(11): 1410. CrossRef The Management of Hematopoietic Stem Cell Transplant in People with HIV
Jana K. Dickter, Courtney Moc Willeford
Viruses.2024; 16(10): 1560. CrossRef Crossing Age Boundaries: The Unifying Potential of Presepsin in Sepsis Diagnosis Across Diverse Age Groups
Edmilson Leal Bastos de Moura, Rinaldo Wellerson Pereira
Journal of Clinical Medicine.2024; 13(23): 7038. CrossRef Introduction of short course treatment for latent tuberculosis infection at a primary care facility for refugees in Winnipeg, Canada: A mixed methods evaluation
Claudyne Chevrier, Mariana Herrera Diaz, Zulma Vanessa Rueda, Shivoan Balakumar, Margaret Haworth-Brockman, Diana Marcela Marin, Afsaneh Oliver, Pierre Plourde, Yoav Keynan
Frontiers in Public Health.2023;[Epub] CrossRef Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges
Gino Agbota, Maryline Bonnet, Christian Lienhardt
Pathogens.2023; 12(3): 362. CrossRef Genotyping of Mycobacterium tuberculosis complex isolated from humans and animals in northeastern Iran
Kiarash Ghazvini, Reza Khoshbakht, Keyvan Tadayon, Nader Mosavari, Hamid Reza BahramiTaghanaki, Gholam Reza Mohammadi, Mohammad Rashti Baf, Kimiya Nourian, Amin Samiei, Mahdis Ghavidel
Scientific Reports.2023;[Epub] CrossRef Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials
Dawit Getachew Assefa, Ahmed Bedru, Eden Dagnachew Zeleke, Solomon Emiru Negash, Dejene Tolossa Debela, Wondowsen Molla, Nebiyu Mengistu, Tigist Tekle Woldesenbet, Neway Fekede Bedane, Violet Dismas Kajogoo, Mary Gorret Atim, Tsegahun Manyazewal
Archives of Public Health.2023;[Epub] CrossRef Treatment strategies for the latent tuberculosis infections
Hui Cao, Baojun Song, Yicang Zhou
Journal of Mathematical Biology.2023;[Epub] CrossRef Determining the Need for Additional Testing With Quantiferon TB Gold in Patients With Positive Tuberculin Skin Tests and a History of BCG Vaccination
Antony J Arumairaj, Hansang Park, Fernando Quesada, Brian Altonen, Shobhana Chaudhari, Joseph Mattana, Imnett Habtes
Cureus.2023;[Epub] CrossRef Chapitre 15: Le suivi du rendement du programme de lutte antituberculeuse
Courtney Heffernan, Margaret Haworth-Brockman, Pierre Plourde, Tom Wong, Giovanni Ferrara, Richard Long
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.2023; 7(6): 526. CrossRef Exploring the ethics of tuberculosis human challenge models
Abie Rohrig, Josh Morrison, Gavriel Kleinwaks, Jonathan Pugh, Helen McShane, Julian Savulescu
Journal of Medical Ethics.2023; : jme-2023-109234. CrossRef Chapter 15: Monitoring tuberculosis program performance
Courtney Heffernan, Margaret Haworth-Brockman, Pierre Plourde, Tom Wong, Giovanni Ferrara, Richard Long
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.2022; 6(sup1): 229. CrossRef Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment
Mohsen Heidary, Maryam Shirani, Melika Moradi, Mehdi Goudarzi, Ramin Pouriran, Tayebe Rezaeian, Saeed Khoshnood
European Journal of Microbiology and Immunology.2022; 12(1): 1. CrossRef Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study
Andrew Kazibwe, Bonniface Oryokot, Levicatus Mugenyi, David Kagimu, Abraham Ignatius Oluka, Darlius Kato, Simple Ouma, Edmund Tayebwakushaba, Charles Odoi, Kizito Kakumba, Ronald Opito, Ceasar Godfrey Mafabi, Michael Ochwo, Robert Nkabala, Wilber Tusiimir
PLOS ONE.2022; 17(5): e0266285. CrossRef Clinical-Epidemiological Characteristics and Outcomes of Latent Tuberculosis Treatment at a Tertiary Center in Central-West Brazil from 2017 to 2019
Moara Alves Santa Bárbara Borges, Iago Dib Cunha, Luís Henrique Candini, Vitor Alves de Souza, Paulo Sérgio Sucasas da Costa
Tropical Medicine and Infectious Disease.2022; 7(12): 432. CrossRef Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report
Jae Hong Oh, Seung Pil Ham, Hai-Jin Park
Annals of Dermatology.2021; 33(1): 77. CrossRef Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study
Yeo-Jin Song, Soo-Kyung Cho, Hyoungyoung Kim, Hye Won Kim, Eunwoo Nam, Sang-Cheol Bae, Dae Hyun Yoo, Yoon-Kyoung Sung
Journal of Korean Medical Science.2021;[Epub] CrossRef Current situation of tuberculosis and National Strategic Plan for Tuberculosis Control in Korea
Eunjeong Son, Doosoo Jeon
Journal of the Korean Medical Association.2021; 64(4): 316. CrossRef Optimal control strategy for adherence to different treatment regimen in various stages of tuberculosis infection
Anupam Khatua, Dhiraj Kumar Das, Tapan Kumar Kar
The European Physical Journal Plus.2021;[Epub] CrossRef Risk Factors of Pulmonary Tuberculosis and Countermeasures: A Literature Review
Edza Aria Wikurendra, Globila Nurika, Yenni Gustiani Tarigan, Arie Arizandi Kurnianto
Open Access Macedonian Journal of Medical Sciences.2021; 9(F): 549. CrossRef The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis Screening under Routine Conditions in a Low-Endemicity Setting
A. Wikell, J. Jonsson, R. Dyrdak, A. J. Henningsson, A. Eringfält, T. Kjerstadius, E. Hålldin, H. Baqir, V. Kholod, E. Sturegård, J. Bruchfeld, T. Schön, Christine Y. Turenne
Journal of Clinical Microbiology.2021;[Epub] CrossRef Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review)
Anna Egorova, Elena G. Salina, Vadim Makarov
International Journal of Molecular Sciences.2021; 22(24): 13317. CrossRef Predictive Value of Positive Interferon-Gamma Release Assay for Hemodialysis Patients: A Cross-Sectional Study in a Tertiary Care Hospital in South Korea
Ye Na Kim, Jinyoung Lee, Yeonsoon Jung
Korean Journal of Healthcare-Associated Infection Control and Prevention.2021; 26(2): 96. CrossRef Latent tuberculosis infection: recent progress and challenges in South Korea
Doosoo Jeon
The Korean Journal of Internal Medicine.2020; 35(2): 269. CrossRef Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea
Jinsoo Min, Hyung Woo Kim, Helen R Stagg, Marc Lipman, Molebogeng X Rangaka, Jun-Pyo Myong, Hyeon Woo Yim, Jeong Uk Lim, Yunhee Lee, Hyeon-Kyoung Koo, Sung-Soon Lee, Jae Seuk Park, Kyung Sook Cho, Ju Sang Kim
BMJ Open.2020; 10(2): e034098. CrossRef Anti-tubercular activity of novel class of spiropyrrolidine tethered indenoquinoxaline heterocyclic hybrids
Natarajan Arumugam, Abdulrahman I. Almansour, Raju Suresh Kumar, Shatha Ibrahim Alaqeel, Vagolu Siva Krishna, Dharmarajan Sriram
Bioorganic Chemistry.2020; 99: 103799. CrossRef Immune checkpoint inhibitors and tuberculosis: an old disease in a new context
Ewan A Langan, Victoria Graetz, Judith Allerheiligen, Detlef Zillikens, Jan Rupp, Patrick Terheyden
The Lancet Oncology.2020; 21(1): e55. CrossRef Single-step synthesis and in vitro anti-mycobacterial activity of novel nitrofurantoin analogues
Nonkululeko H. Zuma, Frans J. Smit, Ronnett Seldon, Janine Aucamp, Audrey Jordaan, Digby F. Warner, David D. N'Da
Bioorganic Chemistry.2020; 96: 103587. CrossRef Mini-open anterior approach focal cleaning combined with posterior internal fixation for thoracolumbar tuberculosis: Follow-up of 149 cases
Dexin Hu, Jun Fei, Genjun Chen, Yongjie Yu, Zhen Lai
Asian Journal of Surgery.2020; 43(1): 78. CrossRef Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection
Ock-Hwa Kim, Kyung-Wook Jo, Shinhee Park, Yong-Ha Jo, Mi-Na Kim, Heungsup Sung, Tae Sun Shim, Katalin Andrea Wilkinson
PLOS ONE.2020; 15(6): e0234700. CrossRef A Targeted Screening Program for Latent Tuberculosis Infection Among Hematopoietic Cell Transplant Recipients
Andrea Sosa-Moreno, Masahiro Narita, Christopher Spitters, Michelle Swetky, Sara Podczervinski, Margaret L Lind, Leona Holmberg, Catherine Liu, Raleigh Edelstein, Steven A Pergam
Open Forum Infectious Diseases.2020;[Epub] CrossRef Appearance and morphologic features of laryngeal tuberculosis using laryngoscopy
Jian Zang, Ying Tian, Xuejun Jiang, Xu-Yong Lin
Medicine.2020; 99(51): e23770. CrossRef Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds
André Campaniço, Shrika G. Harjivan, Digby F. Warner, Rui Moreira, Francisca Lopes
International Journal of Molecular Sciences.2020; 21(22): 8854. CrossRef Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: A multicentre cohort analysis
Seon-Sook Han, Su Jin Lee, Jae-Joon Yim, Jin Hwa Song, Eun Hye Lee, Young Ae Kang, Lei Gao
PLOS ONE.2019; 14(9): e0222810. CrossRef Factors Influencing the Diagnosis and Treatment of Latent Tuberculosis among Contacts in Congregated Settings in Korea
Ahreum Kim, Minhyeok Choi
Journal of Korean Medical Science.2019;[Epub] CrossRef Diagnosis and treatment of latent tuberculosis infection in patients undergoing treatment with immunobiologic agents: a four-year experience in an endemic area
Diana Maria de Almeida Lopes, Valéria Goes Ferreira Pinheiro, Helena Serra Azul Monteiro
Jornal Brasileiro de Pneumologia.2019;[Epub] CrossRef Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis
Marie Nancy Séraphin, HsiaoChu Hsu, Helena J. Chapman, Joanne L. de Andrade Bezerra, Lori Johnston, Yang Yang, Michael Lauzardo
BMC Public Health.2019;[Epub] CrossRef Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers
Kyung-Wook Jo, Ju Sang Kim, Hyouk-Soo Kwon, Yea Eun Park, Ja Young Kim, Min Jee Hong, Tae Sun Shim
Respiratory Medicine.2019; 158: 42. CrossRef Towards optimal treatment for latent Mycobacterium tuberculosis infection
Ibrahim Abubakar, Jeremiah Chakaya, Markus Maeurer, Alimuddin Zumla
The Lancet Respiratory Medicine.2019; 7(3): 195. CrossRef Design of hybrid molecules as antimycobacterial compounds: Synthesis of isoniazid-naphthoquinone derivatives and their activity against susceptible and resistant strains of Mycobacterium tuberculosis
Wallace J. Reis, Ícaro A.O. Bozzi, Matheus F. Ribeiro, Priscila C.B. Halicki, Laís A. Ferreira, Pedro E. Almeida da Silva, Daniela F. Ramos, Carlos A. de Simone, Eufrânio N. da Silva Júnior
Bioorganic & Medicinal Chemistry.2019; 27(18): 4143. CrossRef Demanding an end to tuberculosis
Justine Fargher, Anja Reuter, Jennifer Furin
Current Opinion in HIV and AIDS.2019; 14(1): 21. CrossRef Quality of life of patients on treatment for latent tuberculosis infection: a mixed-method study in Stockholm, Sweden
Jad Shedrawy, Lena Jansson, Isac Röhl, Asli Kulane, Judith Bruchfeld, Knut Lönnroth
Health and Quality of Life Outcomes.2019;[Epub] CrossRef Nutritional Adequacy and Latent Tuberculosis Infection in End-Stage Renal Disease Patients
Seung Don Baek, Soomin Jeung, Jae-Young Kang
Nutrients.2019; 11(10): 2299. CrossRef Diagnosis and treatment of latent tuberculosis infection
Jinsoo Min, Ju Sang Kim
Journal of the Korean Medical Association.2019; 62(1): 11. CrossRef Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
Eun Hye Lee, Seung Hyun Yong, Ah Young Leem, Sang Hoon Lee, Song Yee Kim, Kyung Soo Chung, Ji Ye Jung, Moo Suk Park, Young Sam Kim, Joon Chang, Young Ae Kang
Open Forum Infectious Diseases.2019;[Epub] CrossRef The Comparison Study between Tuberculin Skin Test and Interferon Gamma Release Assay in BCG-Vaccinated Healthy Donors
Yoon-Sung Choi, Sunghyun Kim
Biomedical Science Letters.2018; 24(2): 138. CrossRef PREVALENCE OF DRUG RESISTANCE TO FIRST LINE DRUGS AMONG TUBERCULOSIS PATIENTS IN ASTANA
ZH. K. RАKISHEVА, G. S. BАLАSАNYANTS, А. S. АKISHEVА, А. B. TSEPKE, N. S. SOLOVIEVА
TUBERCULOSIS AND LUNG DISEASES.2018; 96(8): 50. CrossRef
|